1.5) 379 53 0.950 25 (67.six) 12 (32.4) 45 (44.6) 56 (55.four) 69 (40.1) 103 (59.9) 32 (26.2) 90 (73.8) 171 261 0.001 36 (97.3) 1 (1.7) 98 (97) 3 (three.0) 154 (89.five) 18 (10.five) 117 (95.9) five (4.1) 405 27 0.086 36 (97.three) 1 (2.7) 94 (93.1) 7 (six.9) 155 (90.1) 17 (9.9) 106 (86.9) 16 (13.1) 391 41 0.199 33 (89.two) 4 (10.8) 87 (86.1) 14 (13.9) 127 (73.eight) 45 (26.2) 88 (72.1) 34 (27.9) 335 97 0.05 34 (91.9) 3 (eight.1) 91 (90.1) 10 (9.9) 143 (83.1) 29 (16.9) 103 (84.four) 19 (15.six) 371 61 0.277 16 (43.two) 21 (56.eight) 54 (53.five) 47 (46.5) 73 (42.four) 99 (57.six) 48 (39.three) 74 (60.7) 191 241 0.178 5 (13.five) 2 (five.4) 14 (37.eight) 14 (37.eight) two (five.4) 8 (7.9) 6 (5.9) 34 (33.7) 47 (46.5) 6 (5.9) 5 (two.9) 5 (two.9) 43 (25) 109 (63.4) 10 (5.8) 0 (0) four (3.three) 37 (30.three) 73 (59.8) 8 (six.6) 18 17 128 243 26 0.05 12 (32.4) 19 (51.four) three (8.1) 3 (8.1) 29 (28.7) 53 (52.five) 12 (11.9) 7 (6.9) 49 (28.five) 90 (52.three) 24 (14) 9 (5.2) 29 (23.8) 63 (51.6) 24 (19.7) 6 (four.9) 119 225 63 25 0.772 27 (73.0) 10 (27.0) 71 (70.3) 30 (29.7) 114 (66.3) 58 (33.7) 84 (68.9) 38 (31.1) 296 136 0.827 two (five.4) 22 (59.5) 13 (35.1) five (five.0) 50 (49.five) 46 (45.five) 12 (7.0) 61 (35.5) 99 (57.six) 9 (7.four) 43 (35.two) 70 (57.four) 28 176 228 0.057 (n = 101) Double 10 fold (n = 172) (n = 122) (n = 432) Triple Total P ValueZhang et
1.5) 379 53 0.950 25 (67.six) 12 (32.four) 45 (44.6) 56 (55.four) 69 (40.1) 103 (59.9) 32 (26.two) 90 (73.8) 171 261 0.001 36 (97.three) 1 (1.7) 98 (97) three (three.0) 154 (89.five) 18 (ten.five) 117 (95.9) 5 (4.1) 405 27 0.086 36 (97.3) 1 (2.7) 94 (93.1) 7 (6.9) 155 (90.1) 17 (9.9) 106 (86.9) 16 (13.1) 391 41 0.199 33 (89.2) four (ten.eight) 87 (86.1) 14 (13.9) 127 (73.eight) 45 (26.2) 88 (72.1) 34 (27.9) 335 97 0.05 34 (91.9) 3 (8.1) 91 (90.1) ten (9.9) 143 (83.1) 29 (16.9) 103 (84.four) 19 (15.six) 371 61 0.277 16 (43.two) 21 (56.eight) 54 (53.five) 47 (46.five) 73 (42.four) 99 (57.6) 48 (39.three) 74 (60.7) 191 241 0.178 5 (13.5) two (five.4) 14 (37.eight) 14 (37.8) two (5.four) 8 (7.9) six (five.9) 34 (33.7) 47 (46.five) six (five.9) 5 (two.9) five (2.9) 43 (25) 109 (63.4) 10 (five.eight) 0 (0) four (3.3) 37 (30.three) 73 (59.eight) 8 (6.six) 18 17 128 243 26 0.05 12 (32.four) 19 (51.4) 3 (8.1) three (eight.1) 29 (28.7) 53 (52.five) 12 (11.9) 7 (six.9) 49 (28.five) 90 (52.three) 24 (14) 9 (five.two) 29 (23.8) 63 (51.six) 24 (19.7) six (four.9) 119 225 63 25 0.772 27 (73.0) ten (27.0) 71 (70.three) 30 (29.7) 114 (66.three) 58 (33.7) 84 (68.9) 38 (31.1) 296 136 0.827 2 (five.4) 22 (59.5) 13 (35.1) five (five.0) 50 (49.5) 46 (45.five) 12 (7.0) 61 (35.five) 99 (57.six) 9 (7.4) 43 (35.two) 70 (57.four) 28 176 228 0.057 (n = 101) Double ten fold (n = 172) (n = 122) (n = 432) Triple Total P ValueZhang et al. BMC Cancer (2017) 17:Web page 7 ofTable 4 The analysis of good numbers of biomarkers in all lung cancer patients (Continued)Yes Peritoneum No Yes Validation group No. Neg (n = 27) Fundamental Characteristics Age 2 (7.four) 10 (37.0) 15 (55.six) Sex 18 (66.7) 9 (33.three) Histological classification 7 (25.9) 15 (55.six) 1 (3.7) five (18.5) Stages 5 (18.5) 5 (18.5) six (22.two) 11 (40.7) 0 (0.0) Smoke status 15 (55.six) 12 (44.4) Metastasis Brain 27 (100.0) 0 (0.0) Bone 27 (one GAS6 Protein Purity & Documentation hundred.0) 0 (0.0) Liver No Yes Adrenal gland 27 (one hundred.0) 0 (0.0) Lymph node 19 (70.four) 8 (29.6) Intrapulmonary 26 (96.3) 1 (3.7) 105 (89.0) 13 (11.0) 130 (80.7) 31 (19.three) 114 (87.7) 16 (12.three) 375 61 0.064 58 (49.two) 60 (50.8) 50 (31.1) 111 (68.9) 40 (30.8) 90 (69.2) 167 269 0.001 111 (94.1) 7 (5.9) 149 (92.5) 12 (7.five) 122 (93.eight) eight (6.two) 409 27 0.525 26 (96.three) 1 (three.7) 111 (94.1) 7 (5.9) 140 (87.0) 21 (13.0) 106 (81.5) 24 (18.five) 383 53 0.05 103 (87.3) 15 (12.7) 123 (76.four) 38 (23.six) 87 (66.9) 43 (33.1) 340 96 0.001 107 (90.7) 11 (9.3) 134 (83.2) 27 (16.eight) 110 (84.6) 20 (15.4) 378 58 0.05 62 (52.five) 56 (47.5) 65 (40.4) 96 (59.6) 49 (37.7) 81 (62.3) 191 245 0.05 9 (7.six) 16 (13.six) 26 (22.0) 58 (49.2) 9 (7.six) five (3.1) ten (6.two) 36 (22.four) 103 (64.0) 7 (4.3) 3 (two.3) 7 (5.four) 21 (16.2) 90 (69.two) 9 (19.two) 22 38 89 262 25 0.05 31 (26.three) 57 (48.three) five (4.two) 12 (ten.two) 37 (23) 84 (52.2) 11 (six.8) 7 (four.3) 21 (16.two) 64 (49.two) 7 (five.four) 24 (18.5) 96 220 24 47 0.386 75 (63.6) 43 (36.4) 116 (72.0) 45 (28.0) 98 (75.4) 32 (24.6) 307 129 0.204 8 (6.8) 46 (39.0) 64 (54.two) 10 (six.2) 48 (29.8) 103 (64.0) 11 (8.5) 45 (34.six) 74 (56.9) 31 149 256 0.733 PEDF Protein Gene ID Single (n = 118) Double (n = 161) Triple (n = 130) Total (n = 436) P Value 37 (one hundred) 0 (0.0) 98 (93.7) three (6.3) 162 (94.two) 10 (5.eight) 112 (91.eight) 10 (8.2) 409 23 0.153 0 (0.0) three (3.0) three (1.7) eight (6.6)Zhang et al. BMC Cancer (2017) 17:Page 8 ofTable 4 The evaluation of positive numbers of biomarkers in all lung cancer individuals (Continued)Pleural 25 (92.6) two (7.four) Mediastinal 27 (100.0) 0 (0.0) Peritoneum 27 (100.0) 0 (0.0) 110 (93.two) eight (six.eight) 144 (89.4) 17 (ten.four) 118 (90.eight) 12 (9.two) 399 37 0.269 116 (98.3) 2 (1.7) 152 (94.four) 9 (five.6) 123 (94.six) 7 (five.4) 418 18 0.229 107 (90.7) 11 (9.three) 129 (80.1) 32 (20.eight) 104 (80.0) 26 (20.0) 365 71 0.05Fig. 1 The survival status of lung cancer.
